StpA Mutations Reduce Dalbavancin Efficacy in Bacteria
The study identifies how bacterial envelope remodeling leads to increased antibiotic resistance in Enterococcus faecium.
Updated on Oct. 21, 2026 in Life Sciences
Researchers have identified that missense mutations in the StpA gene contribute to reduced susceptibility to the antibiotic dalbavancin in Enterococcus faecium bacteria. This research-stage finding details a new mechanism of antibiotic resistance involving cell wall envelope remodeling.
Why it matters
Understanding the genetic basis for dalbavancin resistance is critical for managing hospital-acquired infections, as this mechanism renders the antibiotic ineffective in laboratory models. The study clarifies how specific StpA mutations alter bacterial cell architecture to bypass the drug's activity.
Mutant bacteria showed thicker cell walls enriched in 3-3 cross-links and a global hyperphosphorylation of cell-division regulators. These changes resulted in reduced cell size and a concentration-dependent decrease in dalbavancin binding compared to non-mutated strains.
The players
Enterococcus faecium
A gram-positive bacterium that acts as a common commensal organism and a major opportunistic pathogen responsible for hospital-acquired infections.
The details
The StpA protein functions as a serine/threonine phosphatase, an enzyme that removes phosphate groups from proteins to regulate cellular pathways. When missense mutations occur in the StpA flap domain, they trigger downstream envelope remodeling, including elevated levels of MurA, an enzyme essential for peptidoglycan synthesis. This structural alteration, observed in the mutants, physically interferes with the binding affinity of dalbavancin, a glycopeptide antibiotic that typically targets the cell wall.
Timeline
- 2026-10-21
The findings were published in a peer-reviewed research article.
The Tech Race
This study expands our understanding of bacterial survival strategies against glycopeptides, moving beyond the well-documented vancomycin resistance pathways. It highlights a critical research trajectory focused on identifying how pathogens evolve to bypass newer, potent antibiotics.
This discovery provides researchers with a new genetic marker to monitor for emerging antibiotic resistance in clinical diagnostics. It does not currently alter standard treatment protocols for patients, as the findings are limited to controlled laboratory and insect models.
The takeaway
This study reveals that StpA mutations represent a distinct, non-canonical path to drug resistance in clinical enterococci. Researchers should track future studies investigating if these mutations emerge in clinical isolates from patients receiving long-term glycopeptide therapy.
Further reading
For broader context on microbial evolution and antibiotic research, visit Life Sciences.
More information
Read the complete peer-reviewed research article.
Source note: This article includes information reported by Nature.
